So when Dr. Jay says the FDA “pushed back,” your big concern is that CytoDyn didn’t push right back? No questions come to mind about why the FDA “pushed back” in the first place if the data they had access to would’ve supported a change to 4 doses?
That, my friend, is called “missing the forrest for the trees”.
I’ll leave aside the questionable semantic hair-splitting involved with defining “pushed back” as meaning “the FDA was open to it, they just wanted CytoDyn to push back,” and not “the FDA denied it.”